Vitamin D supplementation for seniors: clinical risks and benefits

Every week, our care team fields the same cluster of questions from families. "Should we double the dose during winter?" "Mom's specialist ordered a one-time mega-shot — is that better than a daily pill?" "We read online that vitamin D prevents dementia, so we started her on 5,000 IU capsules from the drugstore." These are not fringe concerns. They are the questions that shape daily practice in any nursing or rehabilitation setting that takes nutritional screening seriously, and the answers are more nuanced than the supplement aisle suggests.

We have spent years watching the pendulum swing on vitamin D advice, and we have watched residents pay the price when that swing lands in the wrong direction. Bone health, fall risk, muscle strength, and recovery after hip fracture all sit downstream of vitamin D status — and so do some of the more troubling prescribing patterns we see in post-acute care. Here is what the current clinical evidence actually supports, where the safety margins begin to narrow, and how we approach supplementation for residents and the families who advocate for them.

The Clinical Threshold: Defining Sufficient Vitamin D Levels for Seniors

The first question we ask when a new resident arrives with a vitamin D bottle in their medication bag is not "how much are you taking?" but "what is your serum 25(OH)D level, and when was it last drawn?" Serum 25-hydroxyvitamin D — the storage form of the vitamin that circulates in the bloodstream — is the standard biomarker, and it gives us something a pill bottle never will: a number that reflects what the body is actually doing with the supplement.

The widely accepted threshold for skeletal sufficiency in adults is a serum 25(OH)D concentration of at least 50 nmol/L, which converts to 20 ng/mL. Below that line, the risk of osteomalacia (the softening of adult bone that mimics osteoporosis but is fully reversible with repletion) rises sharply, and so does the risk of secondary hyperparathyroidism, which quietly leaches calcium from the skeleton. Above approximately 75 nmol/L (30 ng/mL), the additional clinical benefit for bone appears to plateau. We are not trying to push vitamin D levels into the "high normal" range that consumer-facing labs sometimes promote; we are trying to clear a known deficiency threshold and stay there.

This matters for caregivers because the most common error we see is dose escalation in the absence of a level. A resident who has been stable at 60 nmol/L for two years on a daily multivitamin does not need 4,000 IU capsules, and adding them does not deliver proportional bone benefit. It does, however, begin to consume the safety margin that we will discuss below.

A serum 25(OH)D level above 50 nmol/L (20 ng/mL) is the working target for skeletal health in older adults; pushing higher does not appear to add measurable bone benefit.

Standardized Dosing Versus the Dangers of Annual Bolus Regimens

If you take one thing from this article, take this: the dosing schedule matters as much as the dose.

The Institute of Medicine established the Recommended Dietary Allowance for vitamin D at 800 IU (20 mcg) daily for adults over age 70, compared with 600 IU (15 mcg) daily for adults aged 1 to 70. The International Osteoporosis Foundation goes a step further, recommending an intake of 800 to 1,000 IU per day for adults aged 60 and over to support both muscle strength and bone health. These are not aggressive numbers. They are physiological — designed to maintain sufficiency in a population whose skin synthesizes less vitamin D from sunlight, whose kidneys convert less of the storage form to the active hormone, and whose dietary intake is often marginal.

The safe upper intake level for adults, set by the Institute of Medicine, is 4,000 IU per day. That ceiling exists for a reason. Vitamin D is fat-soluble, which means excess is not simply excreted the way excess water-soluble vitamins are; it accumulates in adipose tissue and the liver, and at sustained high intake it produces hypercalcemia — elevated blood calcium — that can damage the kidneys, precipitate confusion, and in severe cases trigger cardiac arrhythmias.

We have watched residents arrive from acute care with standing orders for far more alarming doses. The most common culprit is the annual bolus: a single oral or intramuscular dose intended to "carry" a patient through the year. The clinical trial that established the danger of this approach — the Sanders et al. study published in 2010 — randomized older women to a single annual 500,000 IU oral dose and found, counterintuitively, that the high-dose group experienced a significantly higher rate of falls and fractures than the placebo group. The mechanism appears to involve a transient surge in serum calcium followed by a rebound period of relative hypocalcemia and PTH-driven bone resorption; whatever the precise pathway, the clinical signal has been reproduced in subsequent trials and is now treated as established harm rather than a hypothesis.

A single 500,000 IU annual bolus of vitamin D has been shown in randomized trials to increase, not decrease, falls and fractures in older women.

For families, this translates into a practical question worth asking any specialist who proposes a once-yearly injection: "What outcome are you optimizing for, and is the daily alternative on the table?" In our setting, the answer is almost always the daily alternative.

The 2024 Endocrine Society Shift: Targeted Supplementation for the Over-75s

The most important shift in geriatric vitamin D guidance in the past decade is the move away from universal screening and toward targeted empirical supplementation in the oldest adults. The Endocrine Society's 2024 update reflects a maturation of the evidence base: decades of population-level data have not demonstrated meaningful non-skeletal benefits from supplementation in healthy younger adults, while the skeletal and muscular case for supplementation in adults 75 and older has only grown stronger.

Why 75? Three converging reasons. First, the prevalence of frank deficiency rises sharply in that age band, driven by reduced cutaneous synthesis, reduced renal activation, lower dietary intake, and more time indoors during the months when UV exposure is marginal. Second, the consequences of deficiency compound in this population — a hip fracture at 78 carries a markedly higher one-year mortality than the same fracture at 68. Third, the response curve between supplementation and fall reduction is steepest in the oldest cohort, where even modest improvements in muscle strength translate into measurable reductions in injurious falls.

For our residents, the practical implication is straightforward. We do not need a lab order to start a daily 800–1,000 IU supplement in an 82-year-old with a recent fall and a diet that includes little fortified dairy or fatty fish. We do need that order to justify higher doses, and we need a baseline serum level before we ever cross 2,000 IU per day in someone with normal renal function. For residents with significant renal impairment — and a meaningful fraction of our post-acute population falls into this group — the calculus changes further, because the kidney is where the storage form is converted to active calcitriol, and that conversion is impaired when eGFR falls below approximately 30 mL/min/1.73 m². Calcitriol or active analogs may be required in those cases, and a clinician with renal expertise should be directing the regimen.

Navigating the Interaction Between Calcium, Muscle Function, and Bone Density

Vitamin D does not work alone. We think of it as the facilitator that makes calcium usable, and the two are so tightly coupled that supplementation decisions should never be made in isolation. The intestine requires adequate vitamin D to absorb dietary calcium efficiently; without sufficient vitamin D, calcium absorption drops meaningfully, even when dietary intake appears adequate on a menu audit. That malabsorption is what eventually drives secondary hyperparathyroidism and the slow architectural collapse of trabecular bone.

For residents who can tolerate dietary calcium — regular servings of dairy or fortified alternatives, along with leafy greens and certain fish — vitamin D supplementation often produces a meaningful improvement in bone mineral density over 12 to 24 months. For residents who cannot meet calcium targets through diet, or who are on proton pump inhibitors that further reduce absorption, the conversation shifts toward combined calcium and vitamin D supplementation. The mineral is doing nothing useful in a pill bottle if the vitamin that gates its uptake is missing from the regimen, and vice versa.

The muscle side of the equation is what families tend to overlook. Vitamin D receptors are expressed in skeletal muscle, and deficiency produces a measurable proximal myopathy — weakness in the hip flexors and shoulder girdle that is distinct from sarcopenia but often mistaken for it. We have seen residents who were being worked up for neurological disease whose "weakness" resolved within three months of repleting a 25(OH)D level that turned out to be below the sufficiency threshold. The point is not to promise a miracle; the point is to rule out a treatable contributor before accepting that weakness is the new baseline.

Vitamin D is the gatekeeper for calcium absorption and a direct contributor to proximal muscle strength; supplementing one without addressing the other leaves measurable benefit on the table.

There is also a timing consideration that caregivers rarely receive but that we apply routinely. Calcium carbonate is best absorbed with food and can compete with other medications, including levothyroxine and certain antibiotics, for intestinal uptake. Calcium citrate is more forgiving and does not require gastric acid for absorption, which makes it a better default for older adults on proton pump inhibitors. Vitamin D, being fat-soluble, is absorbed more efficiently when taken with a meal that contains some fat — a piece of toast with butter is enough — and there is no advantage to splitting the dose across the day. Once daily is fine.

Addressing the Limits of Evidence: What We Still Don't Know About Non-Skeletal Benefits

We owe families honest answers when they ask, and the honest answer to "Does vitamin D prevent dementia?" is that the clinical trial evidence does not yet support that claim. Observational studies have repeatedly shown an association between low serum 25(OH)D and incident cognitive decline, but association is not causation, and the randomized trials that have tested high-dose supplementation for cognitive endpoints have produced equivocal results. The same pattern holds for cardiovascular outcomes, cancer prevention, and immune function in older adults — suggestive observational data, inconclusive intervention evidence.

We flag this clearly because the alternative — allowing families to believe that escalating vitamin D doses will protect against cognitive decline — produces two real harms. The first is the substitution effect: families sometimes deprioritize interventions with stronger evidence (vascular risk factor control, physical activity, hearing correction, social engagement) in favor of an easy pill. The second is the dose-escalation effect we discussed earlier, where the belief that "more is better" pushes residents past the safety margin without clinical justification.

The unknowns also extend into our own population. There is no high-quality evidence base for individualized dosing in institutionalized seniors with severe renal impairment, where the standard conversion pathway is compromised and standard supplementation may be insufficient. In those residents, decisions are necessarily individualized, made in collaboration with a clinician who can interpret the full clinical picture rather than apply a guideline designed for community-dwelling older adults.

How We Approach Supplementation in Daily Practice

Here is the framework our team uses, and the one we share with families who ask for a clear answer rather than a literature review.

For adults aged 75 and older, we recommend a daily vitamin D supplement of 800 to 1,000 IU without routine screening. This is the Endocrine Society's empirical position and the dose range supported by the International Osteoporosis Foundation for muscle and bone health. For adults aged 60 to 74, we recommend the same range when dietary intake is poor, sun exposure is limited, or a recent serum level has come back below 50 nmol/L. We do not recommend annual bolus doses of 500,000 IU under any circumstance, and we actively counsel against them when they appear on a transfer summary. We do not push daily doses above 2,000 IU without a documented clinical reason and a recent serum level, and we treat the 4,000 IU IOM ceiling as a hard stop for unsupervised supplementation.

We also treat vitamin D as one piece of a larger nutritional and functional picture. A daily supplement does not replace a calcium-aware menu, a falls assessment, a strength and balance program, or the kind of regular sunlight exposure that is safe and practical for the individual resident. When families ask whether a vitamin is "enough," the most reassuring answer is also the most honest: it is one layer of protection, and the other layers matter.

The dignity we preserve in long-term care is built from many small, well-considered choices. Getting the vitamin D regimen right is one of those choices — modest in cost, generous in payoff when applied with the evidence we actually have.